Zacks Investment Research
16 Jul 2026, 16:51 UTC · 1h ago
Abbott Q2 Earnings & Revenues Top Estimates, Stock Up in Pre-market
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
16 Jul 2026, 16:51 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
5 claims · each scored for market impact
Abbott reported Q2 2026 adjusted earnings of $1.31 per share, beating the Zacks Consensus Estimate by 2.34%. — Earnings beats typically drive positive short-term price action, as evidenced by the 3.2% pre-market rise.
+0.40Abbott's Q2 sales increased 13.0% year-over-year to $12.59 billion, surpassing the consensus estimate by 0.91%. — Strong top-line growth and a beat against estimates indicate healthy demand and operational execution.
+0.30Medical Devices sales grew 8.4% on a comparable basis, led by a 13.4% increase in Electrophysiology sales. — Consistent growth in the high-margin Medical Devices segment supports long-term valuation.
+0.20Continue reading
6 related stories
Top 3 movers · tap to explore
Nutrition sales declined 3.1% year-over-year, with U.S. Nutrition remaining particularly weak, down 9.0%. — Significant weakness in the domestic nutrition market represents a drag on overall growth and potential demand issues.
Rapid and Molecular Diagnostics sales declined 8.0% on a comparable basis due to lower respiratory virus testing revenues. — Highlights a decline in pandemic-era or seasonal testing revenue, though it is a known trend.
-0.10Which stocks this story touches
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
21m ago
